While purchasing medicine - It is important that you let us know what other medicine you are using.
This is for preventing unwanted drug interactions.


Want to ask us a professional question ? Call us or Connect VIA Skype







Skype Me™!
 
 



 
 
 
 

OXALIPLATIN EBEWE
Home >> Search Drug By Letter >> Search Drug By Letter: O >> OXALIPLATIN EBEWE
Search Drug By Letter : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

OXALIPLATIN EBEWE
 
Package(a):
VIAL: 1 x 50 mg.
Dosage(a):
For adults only. IV use only.
The recommended dose of in adjuvant setting is 85mg/m2 IV, repeated every two weeks for 12 cycles (6 months). The recommended dose for treatment of metastatic colorectal cancer is 85mg/m2 IV repeated every 2 weeks.
Dosage given should be adjusted according to tolerability.
Should always be administered before fluoropyrimidines.
Prescribing Restrictions:   Kupah Pharmacy Only Medical Division Approval 

Package(b):
VIAL: 1 x 100 mg.
Dosage(b):
For adults only. IV use only.
The recommended dose of in adjuvant setting is 85mg/m2 IV, repeated every two weeks for 12 cycles (6 months). The recommended dose for treatment of metastatic colorectal cancer is 85mg/m2 IV repeated every 2 weeks.
Dosage given should be adjusted according to tolerability.
Should always be administered before fluoropyrimidines.
Prescribing Restrictions Kupah Pharmacy Only Medical Division Approval 

Package(c):
VIAL: 1 x 150 mg.
Dosage(c):
For adults only. IV use only.
The recommended dose of in adjuvant setting is 85mg/m2 IV, repeated every two weeks for 12 cycles (6 months). The recommended dose for treatment of metastatic colorectal cancer is 85mg/m2 IV repeated every 2 weeks.
Dosage given should be adjusted according to tolerability.
Should always be administered before fluoropyrimidines.
Prescribing Restrictions Kupah Pharmacy Only Medical Division Approval 
 

Indications:
In combination with 5-fluorouracil and folinic acid (FA), is indicated for: Adjuvant treatment of stage III (Duke C) colon cancer after complete resection of the primary tumor; treatment of advanced colorectal cancer.
Contra-Indications:
Hypersensitivity to oxaliplatin or to any of the constituents. Myelosuppression prior to starting first course, as evidenced by baseline. Pregnancy & lactation. See prescribing information for full details.
Special Precautions:
Should only be used in specialised departments of oncology and administered under the supervision of an experienced oncologist. See prescribing information for full details.
Side Effects:
Myelosuppression (neutropenia, thrombocytopenia, anemia. See prescribing information for full details.
Drug Interactions:
See prescribing information for full details.